Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rowan Miller

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Scientific Reports|August 23, 2018
Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAnessHarriett Holme, Aditi Gulati, Rachel Brough, et al.
Cancer Discovery|June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant CancersTimothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Scientific Reports|August 23, 2018
Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAnessHarriett Holme, Aditi Gulati, Rachel Brough, et al.
Cancer Discovery|June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant CancersTimothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Pageof 3